Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.95B 1.69B 1.58B 1.44B 2.72B 186B 2.76B 18.57B 7.27B 93.17B 7.33B 7.17B 311B P/E 2026 *
-5.76x
P/E 2027 * -8.47x
Enterprise Value 1.69B 1.47B 1.37B 1.25B 2.36B 162B 2.4B 16.11B 6.31B 80.87B 6.36B 6.22B 270B EV / Sales 2026 *
9.28x
EV / Sales 2027 * 5.34x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week+6.12%
Current month+12.13%
1 month-16.99%
3 months+18.44%
6 months+19.91%
Current year+23.66%
1 week 31.44
Extreme 31.44
33.71
1 month 29.15
Extreme 29.15
41.1
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap.
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Fiscal year

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%+6.12%-4.86%+22.27% 1.95B
-0.70%+13.34%+75.61%+103.83% 70.51B
+0.99%+1.10%+37.00%+65.57% 54.05B
+1.43%+36.37%+10.68%+505.54% 28.95B
-0.61%+12.51%+54.60%+7.40% 24.05B
-0.21%+0.78%-16.31%-13.53% 23.31B
+9.77%+20.16%+260.17%+472.38% 18.67B
+1.88%+7.03%+46.32%-20.12% 18.37B
0.00%+7.46%+30.95%+623.97% 16.1B
-0.19%-9.82%+34.73%+137.70% 12.72B
Average +1.46%+8.13%+52.89%+190.50% 26.87B
Weighted average by Cap. +0.93%+9.17%+56.62%+169.91%

Financials

2026 *2027 *
Net sales 182M 158M 148M 135M 254M 17.41B 258M 1.74B 680M 8.71B 685M 670M 29.07B 340M 295M 276M 252M 473M 32.41B 481M 3.23B 1.27B 16.22B 1.28B 1.25B 54.13B
Net income -338M -293M -274M -250M -471M -32.24B -479M -3.22B -1.26B -16.14B -1.27B -1.24B -53.84B -240M -208M -195M -178M -335M -22.9B -340M -2.28B -895M -11.46B -902M -882M -38.25B
Net Debt -258M -223M -209M -191M -359M -24.57B -365M -2.45B -960M -12.3B -967M -946M -41.03B -137M -119M -111M -102M -191M -13.1B -195M -1.31B -512M -6.56B -516M -505M -21.88B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
12/08/26 $33.65 +2.94% 84,081
11/08/26 $32.69 +0.31% 938,748
10/08/26 $32.59 +0.99% 1,071,534
07/08/26 $32.27 +1.00% 1,399,666
06/08/26 $31.95 +0.73% 1,188,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.69USD
Average target price
45.75USD
Spread / Average Target
+39.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock